SCHEDULE: Whitefort Capital Increases Stake in Arbutus Biopharma

Whitefort Capital Master Fund has adjusted its position in Arbutus Biopharma, reaching an 8.0% beneficial ownership stake and 9.8% total economic exposure.

Summary

• Whitefort Capital Master Fund, LP reported an 8.0% beneficial ownership stake in Arbutus Biopharma Corp, totaling 15,794,261 common shares.
• The reporting group includes Whitefort Capital Management, LP and its principals, David Salanic and Joseph Kaplan.
• The firm entered into a cash-settled total return swap with Nomura Global Financial Products Inc. for 3,500,000 notional shares.
• The swap agreement has a maturity date of October 29, 2029, and a reference price of $4.28 per share.
• Total economic exposure, including the swap, represents approximately 9.8% of the issuer's outstanding shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development; while the firm is shifting some exposure to derivatives, the maintenance of a significant 9.8% total economic interest signals continued commitment to the issuer.

Positives

• Increased economic exposure to 9.8% suggests strong institutional confidence in the issuer's long-term prospects.
• The use of a long-term swap agreement (maturing 2029) indicates a multi-year investment horizon.

Negatives

• The firm engaged in a sale of 3,500,000 shares on April 27, 2026, simultaneously with the initiation of the swap, indicating a shift from direct ownership to synthetic exposure for a portion of the position.

Risks

• Market volatility affecting the reference price of the swap agreement.
• Counterparty risk associated with the Nomura Global Financial Products Inc. swap agreement.
• Potential for regulatory scrutiny regarding the accumulation of significant economic interest via derivatives.

Future Outlook

The reporting persons maintain a long-term investment perspective, evidenced by the 2029 maturity date of the swap agreement, and continue to monitor the issuer's performance.

Management Comments

• The reporting persons disclaim beneficial ownership of the Subject Shares related to the swap agreement.

Industry Context

StockSavvy.ai notes that institutional investors in the biotech sector are increasingly utilizing total return swaps to maintain economic exposure while managing direct shareholding levels, a common strategy to balance voting power and capital efficiency.

Comparison to Industry Standards

• The 8-10% ownership range is consistent with significant minority positions held by activist or long-term institutional investors in mid-cap biotech firms.
• The use of Nomura as a counterparty for derivative instruments is standard practice for large-scale hedge fund operations.

Stakeholder Impact

• Shareholders may view the increased economic stake as a sign of institutional support.
• The swap structure limits the voting power of the reporting person relative to their total economic exposure.

Next Steps

• Continued monitoring of the issuer's share price relative to the $4.28 reference price.
• Potential future filings if ownership thresholds change by 1% or more.

Key Dates

Recommendation

The filing indicates stable institutional interest. Investors should hold as the firm is not signaling an immediate exit, but the shift to synthetic exposure warrants monitoring for potential future divestment.

Keywords

Arbutus Biopharma, Whitefort Capital, Schedule 13D, Total Return Swap, Institutional Investor, Biotech Investment